The global Central Nervous System Biomarker Detection market size is predicted to grow from US$ 9414 million in 2025 to US$ 16420 million in 2031; it is expected to grow at a CAGR of 9.7% from 2025 to 2031.
Central nervous system biomarker detection refers to the identification of specific biomolecules or physiological indicators related to central nervous system diseases through measurement of body fluids (such as blood, cerebrospinal fluid) or imaging methods, for early diagnosis, disease monitoring, efficacy evaluation, and prognosis prediction of diseases. These biomarkers typically include proteins, genetic and epigenetic markers, metabolites, and imaging markers. The core value of the detection lies in improving the diagnostic accuracy of neurological diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc., and promoting the development of personalized medicine.
In recent years, the global market size for central nervous system biomarker detection has been continuously growing. The increasing burden of diseases, technological advancements, and the development of personalized medicine are the main driving factors. With the intensification of global aging, the number of patients with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease has surged; The breakthroughs in gene sequencing and imaging technology have driven the discovery of biomarkers, and artificial intelligence and machine learning provide more accurate and efficient data analysis for biomarker detection; In addition, biomarkers play an important role in developing personalized healthcare plans, and all of these factors have promoted market expansion. In the global market, well-known companies such as Roche, Merck, Takeda, etc. have occupied a large market share with advanced research facilities, technology, and a large amount of resource investment, and have accumulated rich experience in research and clinical applications. Overall, local enterprises such as Dian Diagnostics are still in the catching up stage, and their competitiveness is gradually improving with the continuous breakthroughs in technology and the gradual expansion of the market. The challenges in the market mainly lie in technological bottlenecks, data privacy and ethical controversies over early diagnosis. The development trend of the future market is technological innovation, improvement of detection accuracy and efficiency, personalized and precise diagnosis and treatment, and further expansion of application fields.
The 鈥淐entral Nervous System Biomarker Detection Industry Forecast鈥� looks at past sales and reviews total world Central Nervous System Biomarker Detection sales in 2024, providing a comprehensive analysis by region and market sector of projected Central Nervous System Biomarker Detection sales for 2025 through 2031. With Central Nervous System Biomarker Detection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Central Nervous System Biomarker Detection industry.
This Insight Report provides a comprehensive analysis of the global Central Nervous System Biomarker Detection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Central Nervous System Biomarker Detection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Central Nervous System Biomarker Detection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Central Nervous System Biomarker Detection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Central Nervous System Biomarker Detection.
This report presents a comprehensive overview, market shares, and growth opportunities of Central Nervous System Biomarker Detection market by product type, application, key players and key regions and countries.
Segmentation by Type:
Genetic Biomarkers Detection
Protein Biomarkers Detection
Metabolic Biomarkers Detection
Neuroimaging Biomarkers Detection
Segmentation by Application:
Disease Diagnosis And Classification
Surveillance
Prognosis
Drug Development
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Merck
Takeda
Pfizer
GSK
Novartis
BristolMyers Squibb
Biogen
Celgene
AbbVie
Johnson And Johnson
Amgen
Eli Lilly
Sanofi
AstraZeneca
Quanterix
Biology Leader
Dian Diagnostics
Roadak
Delta Med Biotech
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Central Nervous System Biomarker Detection Market Size (2020-2031)
2.1.2 Central Nervous System Biomarker Detection Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Central Nervous System Biomarker Detection by Country/Region (2020, 2024 & 2031)
2.2 Central Nervous System Biomarker Detection Segment by Type
2.2.1 Genetic Biomarkers Detection
2.2.2 Protein Biomarkers Detection
2.2.3 Metabolic Biomarkers Detection
2.2.4 Neuroimaging Biomarkers Detection
2.3 Central Nervous System Biomarker Detection Market Size by Type
2.3.1 Central Nervous System Biomarker Detection Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Central Nervous System Biomarker Detection Market Size Market Share by Type (2020-2025)
2.4 Central Nervous System Biomarker Detection Segment by Application
2.4.1 Disease Diagnosis And Classification
2.4.2 Surveillance
2.4.3 Prognosis
2.4.4 Drug Development
2.4.5 Others
2.5 Central Nervous System Biomarker Detection Market Size by Application
2.5.1 Central Nervous System Biomarker Detection Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Central Nervous System Biomarker Detection Market Size Market Share by Application (2020-2025)
3 Central Nervous System Biomarker Detection Market Size by Player
3.1 Central Nervous System Biomarker Detection Market Size Market Share by Player
3.1.1 Global Central Nervous System Biomarker Detection Revenue by Player (2020-2025)
3.1.2 Global Central Nervous System Biomarker Detection Revenue Market Share by Player (2020-2025)
3.2 Global Central Nervous System Biomarker Detection Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Central Nervous System Biomarker Detection by Region
4.1 Central Nervous System Biomarker Detection Market Size by Region (2020-2025)
4.2 Global Central Nervous System Biomarker Detection Annual Revenue by Country/Region (2020-2025)
4.3 Americas Central Nervous System Biomarker Detection Market Size Growth (2020-2025)
4.4 APAC Central Nervous System Biomarker Detection Market Size Growth (2020-2025)
4.5 Europe Central Nervous System Biomarker Detection Market Size Growth (2020-2025)
4.6 Middle East & Africa Central Nervous System Biomarker Detection Market Size Growth (2020-2025)
5 Americas
5.1 Americas Central Nervous System Biomarker Detection Market Size by Country (2020-2025)
5.2 Americas Central Nervous System Biomarker Detection Market Size by Type (2020-2025)
5.3 Americas Central Nervous System Biomarker Detection Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Central Nervous System Biomarker Detection Market Size by Region (2020-2025)
6.2 APAC Central Nervous System Biomarker Detection Market Size by Type (2020-2025)
6.3 APAC Central Nervous System Biomarker Detection Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Central Nervous System Biomarker Detection Market Size by Country (2020-2025)
7.2 Europe Central Nervous System Biomarker Detection Market Size by Type (2020-2025)
7.3 Europe Central Nervous System Biomarker Detection Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Central Nervous System Biomarker Detection by Region (2020-2025)
8.2 Middle East & Africa Central Nervous System Biomarker Detection Market Size by Type (2020-2025)
8.3 Middle East & Africa Central Nervous System Biomarker Detection Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Central Nervous System Biomarker Detection Market Forecast
10.1 Global Central Nervous System Biomarker Detection Forecast by Region (2026-2031)
10.1.1 Global Central Nervous System Biomarker Detection Forecast by Region (2026-2031)
10.1.2 Americas Central Nervous System Biomarker Detection Forecast
10.1.3 APAC Central Nervous System Biomarker Detection Forecast
10.1.4 Europe Central Nervous System Biomarker Detection Forecast
10.1.5 Middle East & Africa Central Nervous System Biomarker Detection Forecast
10.2 Americas Central Nervous System Biomarker Detection Forecast by Country (2026-2031)
10.2.1 United States Market Central Nervous System Biomarker Detection Forecast
10.2.2 Canada Market Central Nervous System Biomarker Detection Forecast
10.2.3 Mexico Market Central Nervous System Biomarker Detection Forecast
10.2.4 Brazil Market Central Nervous System Biomarker Detection Forecast
10.3 APAC Central Nervous System Biomarker Detection Forecast by Region (2026-2031)
10.3.1 China Central Nervous System Biomarker Detection Market Forecast
10.3.2 Japan Market Central Nervous System Biomarker Detection Forecast
10.3.3 Korea Market Central Nervous System Biomarker Detection Forecast
10.3.4 Southeast Asia Market Central Nervous System Biomarker Detection Forecast
10.3.5 India Market Central Nervous System Biomarker Detection Forecast
10.3.6 Australia Market Central Nervous System Biomarker Detection Forecast
10.4 Europe Central Nervous System Biomarker Detection Forecast by Country (2026-2031)
10.4.1 Germany Market Central Nervous System Biomarker Detection Forecast
10.4.2 France Market Central Nervous System Biomarker Detection Forecast
10.4.3 UK Market Central Nervous System Biomarker Detection Forecast
10.4.4 Italy Market Central Nervous System Biomarker Detection Forecast
10.4.5 Russia Market Central Nervous System Biomarker Detection Forecast
10.5 Middle East & Africa Central Nervous System Biomarker Detection Forecast by Region (2026-2031)
10.5.1 Egypt Market Central Nervous System Biomarker Detection Forecast
10.5.2 South Africa Market Central Nervous System Biomarker Detection Forecast
10.5.3 Israel Market Central Nervous System Biomarker Detection Forecast
10.5.4 Turkey Market Central Nervous System Biomarker Detection Forecast
10.6 Global Central Nervous System Biomarker Detection Forecast by Type (2026-2031)
10.7 Global Central Nervous System Biomarker Detection Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Central Nervous System Biomarker Detection Forecast
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche Central Nervous System Biomarker Detection Product Offered
11.1.3 Roche Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Merck
11.2.1 Merck Company Information
11.2.2 Merck Central Nervous System Biomarker Detection Product Offered
11.2.3 Merck Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Merck Main Business Overview
11.2.5 Merck Latest Developments
11.3 Takeda
11.3.1 Takeda Company Information
11.3.2 Takeda Central Nervous System Biomarker Detection Product Offered
11.3.3 Takeda Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Takeda Main Business Overview
11.3.5 Takeda Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Central Nervous System Biomarker Detection Product Offered
11.4.3 Pfizer Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 GSK
11.5.1 GSK Company Information
11.5.2 GSK Central Nervous System Biomarker Detection Product Offered
11.5.3 GSK Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 GSK Main Business Overview
11.5.5 GSK Latest Developments
11.6 Novartis
11.6.1 Novartis Company Information
11.6.2 Novartis Central Nervous System Biomarker Detection Product Offered
11.6.3 Novartis Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Novartis Main Business Overview
11.6.5 Novartis Latest Developments
11.7 BristolMyers Squibb
11.7.1 BristolMyers Squibb Company Information
11.7.2 BristolMyers Squibb Central Nervous System Biomarker Detection Product Offered
11.7.3 BristolMyers Squibb Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 BristolMyers Squibb Main Business Overview
11.7.5 BristolMyers Squibb Latest Developments
11.8 Biogen
11.8.1 Biogen Company Information
11.8.2 Biogen Central Nervous System Biomarker Detection Product Offered
11.8.3 Biogen Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Biogen Main Business Overview
11.8.5 Biogen Latest Developments
11.9 Celgene
11.9.1 Celgene Company Information
11.9.2 Celgene Central Nervous System Biomarker Detection Product Offered
11.9.3 Celgene Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Celgene Main Business Overview
11.9.5 Celgene Latest Developments
11.10 AbbVie
11.10.1 AbbVie Company Information
11.10.2 AbbVie Central Nervous System Biomarker Detection Product Offered
11.10.3 AbbVie Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 AbbVie Main Business Overview
11.10.5 AbbVie Latest Developments
11.11 Johnson And Johnson
11.11.1 Johnson And Johnson Company Information
11.11.2 Johnson And Johnson Central Nervous System Biomarker Detection Product Offered
11.11.3 Johnson And Johnson Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Johnson And Johnson Main Business Overview
11.11.5 Johnson And Johnson Latest Developments
11.12 Amgen
11.12.1 Amgen Company Information
11.12.2 Amgen Central Nervous System Biomarker Detection Product Offered
11.12.3 Amgen Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Amgen Main Business Overview
11.12.5 Amgen Latest Developments
11.13 Eli Lilly
11.13.1 Eli Lilly Company Information
11.13.2 Eli Lilly Central Nervous System Biomarker Detection Product Offered
11.13.3 Eli Lilly Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 Eli Lilly Main Business Overview
11.13.5 Eli Lilly Latest Developments
11.14 Sanofi
11.14.1 Sanofi Company Information
11.14.2 Sanofi Central Nervous System Biomarker Detection Product Offered
11.14.3 Sanofi Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Sanofi Main Business Overview
11.14.5 Sanofi Latest Developments
11.15 AstraZeneca
11.15.1 AstraZeneca Company Information
11.15.2 AstraZeneca Central Nervous System Biomarker Detection Product Offered
11.15.3 AstraZeneca Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 AstraZeneca Main Business Overview
11.15.5 AstraZeneca Latest Developments
11.16 Quanterix
11.16.1 Quanterix Company Information
11.16.2 Quanterix Central Nervous System Biomarker Detection Product Offered
11.16.3 Quanterix Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Quanterix Main Business Overview
11.16.5 Quanterix Latest Developments
11.17 Biology Leader
11.17.1 Biology Leader Company Information
11.17.2 Biology Leader Central Nervous System Biomarker Detection Product Offered
11.17.3 Biology Leader Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.17.4 Biology Leader Main Business Overview
11.17.5 Biology Leader Latest Developments
11.18 Dian Diagnostics
11.18.1 Dian Diagnostics Company Information
11.18.2 Dian Diagnostics Central Nervous System Biomarker Detection Product Offered
11.18.3 Dian Diagnostics Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.18.4 Dian Diagnostics Main Business Overview
11.18.5 Dian Diagnostics Latest Developments
11.19 Roadak
11.19.1 Roadak Company Information
11.19.2 Roadak Central Nervous System Biomarker Detection Product Offered
11.19.3 Roadak Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.19.4 Roadak Main Business Overview
11.19.5 Roadak Latest Developments
11.20 Delta Med Biotech
11.20.1 Delta Med Biotech Company Information
11.20.2 Delta Med Biotech Central Nervous System Biomarker Detection Product Offered
11.20.3 Delta Med Biotech Central Nervous System Biomarker Detection Revenue, Gross Margin and Market Share (2020-2025)
11.20.4 Delta Med Biotech Main Business Overview
11.20.5 Delta Med Biotech Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
